Imatinib (Gleevec®)-induced hepatotoxicity

Walid S. Ayoub, Stephen A. Geller, Tram Tran, Paul Martin, John M. Vierling, F. Fred Poordad

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Imatinib (Gleevec®, Novartis Pharmaceuticals Corp, East Hanover, NJ) is widely used in the treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors. To our knowledge, only one case report of histologically proven Imatinib-induced hepatotoxicity has been reported. We describe another case of hepatotoxicity in a 22-year-old woman including the histopathologic changes and the clinical course after the discontinuation of Imatinib.

Original languageEnglish (US)
Pages (from-to)75-77
Number of pages3
JournalJournal of clinical gastroenterology
Volume39
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes

Keywords

  • Gleevec®
  • Hepatotoxicity
  • Imatinib

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Imatinib (Gleevec®)-induced hepatotoxicity'. Together they form a unique fingerprint.

  • Cite this

    Ayoub, W. S., Geller, S. A., Tran, T., Martin, P., Vierling, J. M., & Poordad, F. F. (2005). Imatinib (Gleevec®)-induced hepatotoxicity. Journal of clinical gastroenterology, 39(1), 75-77.